Effects of indigestible dextrin on postprandial glucose level ,lipid value and incretin secretion in healty subjects and type 2 diabetic patients

Effects of indigestible dextrin on postprandial glucose level ,lipid value and incretin secretion in healty subjects and type 2 diabetic patients - indigestible dextrin and incretin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003186

Enrollment

Registered

2010-02-15

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

No administration of indigestible dextrin Administration of indigestible dextrin once Administration of indigestible dextrin for seven days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diabetic patients and healthy subjects 2.Subjects who provided written informed concent.

Exclusion criteria

Exclusion criteria: 1.Patients who are receiving insulin therapy. 2.Patients who have a severe hepatic dysfunction. 3.Patients who have a severe renal dysfunction.

Design outcomes

Primary

Measure	Time frame
postprandial incretin secretion	—

Secondary

Measure	Time frame
1.postprandial glucose level 2.postprandial lipid level 3.postprandial insulin secretion	—

Countries

Japan

Contacts

Public ContactKiyomi Masuda

Graduate School of Medicine, Yokohama City University Department of Endocrinology and Metabolism

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026